Standard BioTools Inc (NASDAQ: LAB) on Friday, soared 4.90% from the previous trading day, before settling in for the closing price of $1.43. Within the past 52 weeks, LAB’s price has moved between $0.92 and $2.25.
During the last 5-year period, the sales growth of Healthcare Sector giant was 11.61%. The company achieved an average annual earnings per share of 60.26%. With a float of $368.50 million, this company’s outstanding shares have now reached $383.61 million.
Standard BioTools Inc (LAB) Insider Activity
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Standard BioTools Inc is 4.20%, while institutional ownership is 76.12%. The most recent insider transaction that took place on Nov 25 ’25, was worth 9,838,405. In this transaction Director of this company bought 7,550,000 shares at a rate of $1.30, taking the stock ownership to the 71,750,000 shares. Before that another transaction happened on Nov 24 ’25, when Company’s Director bought 150,000 for $1.43, making the entire transaction worth $214,875. This insider now owns 64,200,000 shares in total.
Standard BioTools Inc (LAB) Earnings and Forecasts
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.05 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.03) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 60.26% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 42.89% during the next five years compared to 11.61% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Standard BioTools Inc (LAB) is currently performing well based on its current performance indicators. A quick ratio of 4.14 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.34, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.12 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Looking closely at Standard BioTools Inc (NASDAQ: LAB), its last 5-days average volume was 3.82 million, which is a jump from its year-to-date volume of 1.71 million. As of the previous 9 days, the stock’s Stochastic %D was 87.93%.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 87.76%, which indicates a significant increase from 86.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0821 in the past 14 days, which was higher than the 0.0769 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2900, while its 200-day Moving Average is $1.2219. However, in the short run, Standard BioTools Inc’s stock first resistance to watch stands at $1.5567. Second resistance stands at $1.6133. The third major resistance level sits at $1.6667. If the price goes on to break the first support level at $1.4467, it is likely to go to the next support level at $1.3933. Should the price break the second support level, the third support level stands at $1.3367.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
Market capitalization of the company is 576.85 million based on 384,565K outstanding shares. Right now, sales total 174,430 K and income totals -138,890 K. The company made 19,550 K in profit during its latest quarter, and -34,690 K in sales during its previous quarter.
